Absci Announces New and Expanded Collaboration with Merck


Absci, A Washington-based life science company has announced a collaboration with Merck worth up to $610 million in milestone payments and upfront fees. Under the new agreement, Merck can use enzymes produced by Absci’s amino acid technology.

“Merck’s been a partner of ours in the past, and this is really exciting because it shows that once we’re integrated within an organization, we just start to expand and they utilize our technology not only for manufacturing but for the drug discovery,” said Sean McClain, Founder and CEO of Absci.